Source comparison
BPC-157 Support Post-Workout Recovery: Comparison of Recovery Modalities
BPC-157 (250–500 mcg/day subcutaneous) Activates FAK-paxillin pathway, increases VEGF and growth hormone receptor expression, modulates TNF-alpha and IL-6 7–14 days for subjective improvement in tendinopathy; 10–21 days for documented tissue remodeling changes
This comparison does not assign a generated winner or score.
- BPC-157 (250–500 mcg/day subcutaneous)
- Activates FAK-paxillin pathway, increases VEGF and growth hormone receptor expression, modulates TNF-alpha and IL-6
- 7–14 days for subjective improvement in tendinopathy; 10–21 days for documented tissue remodeling changes
- Highest efficacy in soft tissue injuries (tendons, ligaments, muscle strains); limited data on bone or cartilage
- Strong preclinical (rodent models); minimal controlled human trials; consistent anecdotal reports from sports medicine case series
- Best suited for chronic tendinopathy or delayed-healing soft tissue injuries; not a general soreness remedy
- NSAIDs (ibuprofen 400–800 mg)
- COX-1 and COX-2 enzyme inhibition, reducing prostaglandin synthesis
- 30–60 minutes for pain relief; no acceleration of tissue repair
- Nonspecific. Reduces pain and inflammation broadly without tissue-type preference
- Extensive human data; proven analgesic effect but documented impairment of muscle protein synthesis when used chronically
- Effective for acute pain management; chronic use may delay recovery and impair adaptation
- Cold water immersion (10–15°C for 10–15 min)
- Vasoconstriction reduces metabolite accumulation and inflammatory cell infiltration
- Immediate reduction in perceived soreness; no documented tissue repair acceleration
- Most effective for whole-body or large muscle group soreness; limited impact on localized injuries
- Moderate human evidence; reduces perceived soreness but may blunt hypertrophic adaptations if used immediately post-resistance training
- Useful for symptom management; not ideal immediately after hypertrophy-focused sessions
- Compression garments (15–25 mmHg)
- Increases venous return, reduces muscle oscillation during movement, may limit edema formation
- Subjective soreness reduction within 24–48 hours; no direct tissue repair mechanism
- Effective for general post-exercise soreness; minimal impact on structural injuries
- Moderate human evidence; small to moderate effect sizes for DOMS reduction
- Low risk, modest benefit; useful as adjunct, not primary recovery tool
- Active recovery (low-intensity aerobic work)
- Increases blood flow without imposing mechanical load, facilitates metabolite clearance
- Immediate to 24 hours for perceived soreness reduction
- Nonspecific. Benefits general muscle soreness, not structural tissue damage
- Strong human evidence for DOMS reduction; no evidence of accelerated tissue repair
- Highly effective for general soreness; does not address injury healing